Evidence map›Paper›PMID 42129506›Full record

ArticleNature biotechnology2026

Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models.

A Gupta, R Das, K Reed, T Jeon, Q T C Nguyen, A Rudra, X Ge, S Trongjit, Y S Vanrobaeys, R Langer and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Dual pKa Lipid Nanoparticles for Lung-tropic mRNA Delivery and pH-Programmed Endosomal Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

A Gupta *David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5614-2313
R Das *Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
K Reed *David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
T JeonDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3840-5129
Q T C NguyenDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0009-0006-6007-1988
A RudraDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-1704-5534
X GeCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
S TrongjitDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Y S VanrobaeysBioinformatics & Computing Core Facility of the Swanson Biotechnology Center, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
R LangerDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-4255-0492
R WeisslederCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0828-4143
C GarrisCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA. cgarris@mgh.harvard.edu.
D G AndersonDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. dgander@mit.edu.ORCID http://orcid.org/0000-0001-5629-4798

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Training Grant in Molecular Imaging Research (MGH/HMS)T32CA079443 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2025
$10.1M
FAST-FNA immune cell profiling in HNSCCR01CA257623 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FAQUIN, WILLIAM CLAY, WEISSLEDER, MD, PHD, RALPH · 2021 to 2025
$3.3M
Temporal analysis of the GBM tumor microenvironment during myeloid cell activating therapyR01CA281735 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI RALPH WEISSLEDER, MD, PhD · 2023 to 2026
$2.3M
Combinatorial and computational design of bnAb mRNA vaccines for HIVR61AI161805 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ANDERSON, DANIEL G · 2021 to 2023
$2.1M
Bioorthogonal probe development for highly parallel in vivo imagingR33CA277820 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2023 to 2025
$1.2M
NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA257623NCI NIH HHS R01 CA281735NCI NIH HHS R33 CA277820NCI NIH HHS T32 CA079443NIAID NIH HHS R61 AI161805
6 · The paper itself

Abstract

Although immunotherapy has benefited a subset of persons with cancer, its broader efficacy remains limited, primarily because of an immunosuppressive tumor microenvironment characterized by insufficient numbers of functional tumor-specific T cells, antigen-presenting cells (APCs) and tumor-infiltrating lymphocytes. Here we engineer immune cells in the tumor microenvironment using lipid nanoparticles (LNPs) to deliver immune-remodeling mRNAs (IR-mRNAs) encoding NF-κB-inducing kinase or interferon regulatory factor 8. These IR-mRNAs activate APCs in tumors, significantly increasing activated type 1 conventional dendritic cells, immunostimulatory cytokines and priming antitumor CD8

Identifiers

PMID42129506
PMCPMC13242704

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.